Press Releases

THERAVET PROVIDES ITS HALF-YEAR OPERATIONAL UPDATE OF 2021

 

July 7, 2021

 

TheraVet S.A., a pioneering company in the management of osteoarticular diseases in pets, provides today its half-year operational update ending 30 June 2021....

 

Read more

 

Lire plus

 

PREVIOUS PRESS RELEASES

 

 

 

TheraVet extends the use of BIOCERA-VET to new curative approach of osteosarcoma in dogs

TheraVet announces its 2021 financial calendar

TheraVet: Successful IPO on Euronext Growth® Paris and Brussels

July 2, 2021

 

 

TheraVet (ISIN: BE0974387194 - ticker: ALVET), a biotechnology company specialising in osteoarticular treatments for animals, today announces a new use of BIOCERA-VET in a multidisciplinary approach to the treatment of osteosarcoma in dogs. ...

 

 

 

 

 

Read more

 

Lire plus

June 30, 2021

 

 

TheraVet (ISIN: BE0974387194 - ticker: ALVET), a biotechnology company specialising in osteoarticular treatments for animals, today announces its 2021 financial calendar. ...

 

 

 

 

 

 

 

 

Read more

June 11, 2021

 

 

TheraVet (ISIN: BE0974387194 - ticker: ALVET), a biotechnology company specialising in osteoarticular treatments for animals, is today announcing the results of its successful initial public offering on Euronext Growth® Paris and Brussels. ...

 

To view TheraVet's opening bell ceremony, click here.

 

 

 

 

Read more

TheraVet: Initial Public Offering on Euronext Growth® Brussels and Paris

BIOCERA-VET: a promising alternative to autologous bone graft in canine arthrodesis


TheraVet announces the commercial launch of BIOCERA-VET

May 26, 2021

 

Read more

April 27, 2021

 

Read more

April 01, 2021

 

Read more

Positive results of a single intra-articular injection of VISCO-VET in canine osteoarthritis
Positive results in canine cranial cruciate ligament deficiency
TheraVet raises 4 M€  to accelerate the development of its two veterinary products

March 04, 2021

 

Read more

January 26, 2021

 

Read more

December 10, 2020

 

Read more

TheraVet launches a prospective multicentric clinical trial in canine osteosarcoma
TheraVet completes first regulatory milestones for the US registration (NADA) of VISCO-VET in canine osteoarthritis

November 17, 2020

 

Read more

June 15, 2020

 

Read more

This website uses cookies The website of TheraVet SA uses functional cookies. In case of analysing our traffic or advertising, we also place cookies that share information about your use of our site with our analytics partners, our social media and advertising partners, who may combine it with other information that you’ve provided to them or that they’ve collected from your use of their services.
Show details Hide details
Allow selection Allow all cookies